Regulatory T-cells (Treg) hamper immune responses elicited by cancer vaccines. Therefore, depletion of Treg is being used to improve the outcome of vaccinations.
Methods
We studied whether an alphavirus vector-based immunotherapeutic vaccine changes the number and/or activity of Treg and if Treg depletion improves the efficacy of this vaccine against tumours. The vaccine is based on a Semliki Forest virus (SFV). The recombinant SFV replicon particles encode a fusion protein of E6 and E7 from human papillomavirus (HPV) type 16 (SFVeE6,7).
Results
We demonstrated that SFVeE6,7 immunization did not change Treg levels and their suppressive activity. Depletion of Treg in mice, using the novel anti-folate receptor 4 antibody, did not enhance the immune response induced by SFVeE6,7 immunization. Both the priming and the proliferation phases of the HPV-specific response elicited with SFVeE6,7 were not affected by the immune-suppressive activity of Treg. Moreover, Treg depletion did not improve the therapeutic antitumour response of SFVeE6,7 in a murine tumour model.
Conclusions
The efficacy of the SFVeE6,7 vaccine was not hampered by Treg. Therefore, SFVeE6,7 seems a very promising candidate for the treatment of HPV-induced disease, as it may not require additional immune interventions to modulate Treg activity.
References
1.
DannullJ., SuZ., RizzieriD.Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest2005; 115: 3623–3633.
2.
DellucS., HachemP., RusakiewiczS.Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. Cancer Immunol Immunother2009; 58: 1669–1677.
3.
ImaiH., SaioM., NonakaK.Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci2007; 98: 416–423.
4.
JacobJ.B., KongY.C., NalbantogluI., SnowerD.P., WeiW.Z.Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol2009; 182: 5873–5881.
5.
KottkeT., PulidoJ., ThompsonJ.Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res2009; 69: 7767–7774.
6.
Kudo-SaitoC., SchlomJ., CamphausenK., ColemanC.N., HodgeJ.W.The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res2005; 11: 4533–4544.
7.
LutsiakM.E., SemnaniR.T., DeP.R., KashmiriS.V., SchlomJ., SabzevariH.Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood2005; 105: 2862–2868.
8.
WadaS., YoshimuraK., HipkissE.L.Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res2009; 69: 4309–4318.
9.
ApostolouI., von BoehmerH.In vivo instruction of suppressor commitment in naive T cells. J Exp Med2004; 199: 1401–1408.
10.
BerraondoP., NouzeC., PrevilleX., LadantD., LeclercC.Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res2007; 67: 8847–8855.
11.
DahlbergP.E., SchartnerJ.M., TimmelA., SeroogyC.M.Daily subcutaneous injections of peptide induce CD4+ CD25+ T regulatory cells. Clin Exp Immunol2007; 149: 226–234.
12.
MaksimowM., MiiluniemiM., Marttila-IchiharaF., JalkanenS., HanninenA.Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity. Blood2006; 108: 1298–1305.
13.
SilverP.B., AgarwalR.K., SuS.B.Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. J Immunol2007; 179: 5146–5158.
14.
ZhouG., DrakeC.G., LevitskyH.I.Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood2006; 107: 628–636.
15.
CurielT.J.Regulatory T cells and treatment of cancer. Curr Opin Immunol2008; 20: 241–246.
16.
VisserJ., NijmanH.W., HoogenboomB.N.Frequencies and role of regulatory T cells in patients with (pre) malignant cervical neoplasia. Clin Exp Immunol2007; 150: 199–209.
17.
WangH.Y., WangR.F.Regulatory T cells and cancer. Curr Opin Immunol2007; 19: 217–223.
18.
WolfA.M., WolfD., SteurerM., GastlG., GunsiliusE., Grubeck-LoebensteinB.Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res2003; 9: 606–612.
KimJ.M., RasmussenJ.P., RudenskyA.Y.Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol2007; 8: 191–197.
21.
MillsK.H.Regulatory T cells: friend or foe in immunity to infection?Nat Rev Immunol2004; 4: 841–855.
22.
BanerjeeD.K., DhodapkarM.V., MatayevaE., SteinmanR.M., DhodapkarK.M.Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood2006; 108: 2655–2661.
23.
HussainS.F., PatersonY.CD4+CD25+ regulatory T cells that secrete TGF[beta] and IL-10 are preferentially induced by a vaccine vector. J Immunother2004; 27: 339–346.
24.
DaemenT., RegtsJ., HoltropM., WilschutJ.Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther2002; 9: 85–94.
25.
LiljeströmP., GaroffH.A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y)1991; 9: 1356–1361.
26.
DaemenT., Riezebos-BrilmanA., BungenerL., RegtsJ., DontjeB., WilschutJ.Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine2003; 21: 1082–1088.
27.
DaemenT., Riezebos-BrilmanA., RegtsJ., DontjeB., van der ZeeA., WilschutJ.Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther2004; 9: 733–742.
28.
Riezebos-BrilmanA., RegtsJ., FreyschmidtE.J., DontjeB., WilschutJ., DaemenT.Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther2005; 12: 1410–1414.
29.
Riezebos-BrilmanA., WalczakM., RegtsJ.A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther2007; 14: 1695–1704.
30.
FehérvariZ., SakaguchiS.Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol2004; 16: 203–208.
31.
SakaguchiS.Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol2004; 22: 531–562.
32.
FontenotJ.D., GavinM.A., RudenskyA.Y.Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol2003; 4: 330–336.
33.
HoriS., NomuraT., SakaguchiS.Control of regulatory T cell development by the transcription factor Foxp3. Science2003; 299: 1057–1061.
34.
KhattriR., CoxT., YasaykoS.A., RamsdellF.An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol2003; 4: 337–342.
35.
SakaguchiS., YamaguchiT., NomuraT., OnoM.Regulatory T cells and immune tolerance. Cell2008; 133: 775–787.
36.
ZhengY., RudenskyA.Y.Foxp3 in control of the regulatory T cell lineage. Nat Immunol2007; 8: 457–462.
37.
MorseM.A., HobeikaA.C., OsadaT.Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood2008; 112: 610–618.
38.
PowellD.J.Jr., Felipe-SilvaA., MerinoM.J.Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol2007; 179: 4919–4928.
39.
RechA.J., VonderheideR.H.Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci2009; 1174: 99–106.
40.
CouperK.N., BlountD.G., de SouzaJ.B., SuffaI., BelkaidY., RileyE.M.Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice. J Immunol2007; 178: 4136–4146.
41.
KohmA.P., McMahonJ.S., PodojilJ.R.Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol2006; 176: 3301–3305.
42.
CurtinJ.F., CandolfM., FakhouriT.M.Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS ONE2008; 3: e1983.
43.
YamaguchiT., HirotaK., NagahamaK.Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity2007; 27: 145–159.
44.
ChenG., LiN., ZangY.C.Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum2007; 56: 453–463.
45.
CabreraA., SaezD., CespedesS., AndrewsE., OnateA.Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice. Immunobiology2009; 214: 467–474.
MillerA., CenterR.J., StambasJ.Sindbis virus vectors elicit hemagglutinin-specific humoral and cellular immune responses and offer a dose-sparing strategy for vaccination. Vaccine2008; 26: 5641–5648.
48.
Riezebos-BrilmanA., de MareA., BungenerL., HuckriedeA., WilschutJ., DaemenT.Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J Clin Virol2006; 35: 233–243.
49.
ZhengM., JinN.Y., LiuQ.Immunogenicity and protective efficacy of Semliki Forest virus replicon-based DNA vaccines encoding goatpox virus structural proteins. Virology2009; 391: 33–43.
50.
SutmullerR.P., den BrokM.H., KramerM.Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest2006; 116: 485–494.
51.
TranD.Q., AnderssonJ., HardwickD., BebrisL., IlleiG.G., ShevachE.M.Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/ CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood2009; 113: 5125–5133.
52.
MatsushitaN., Pilon-ThomasS.A., MartinL.M., RikerA.I.Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods2008; 333: 167–179.
53.
TengM.W., SwannJ.B., von ScheidtB.Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res2010; 70: 2665–2674.
54.
TuveS., ChenB.M., LiuY.Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res2007; 67: 5929–5939.
55.
ChuangC.M., HooryT., MonieA., WuA., WangM.C., HungC.F.Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine2009; 27: 684–689.
